
Priya Sriskandarajah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9182101/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood, 2014, 124, 2467-2468.	0.6	57
2	Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncology, The, 2020, 21, 1478-1488.	5.1	41
3	Epidemiology and environmental aspects of marginal zone lymphomas. Best Practice and Research in Clinical Haematology, 2017, 30, 84-91.	0.7	33
4	Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients. Thrombosis Journal, 2015, 13, 21.	0.9	27
5	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma Journal of Clinical Oncology, 2017, 35, 2506-2506.	0.8	22
6	The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world―study: the Royal Marsden Hospital experience. Leukemia and Lymphoma, 2017, 58, 494-497.	0.6	14
7	Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. British Journal of Radiology, 2019, 92, 20180822.	1.0	6
8	Retrospective Cohort Analysis Examining the Efficacy and Safety of (V)DTPACE in Newly Diagnosed and Relapsed/Refractory Myeloma Patients – the UK Experience. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S80.	0.2	1
9	Thrombocytopenia and fever: not just another infection…. BMJ Case Reports, 2016, 2016, bcr2016214669.	0.2	0
10	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. Blood, 2018, 132, 3237-3237.	0.6	0
11	'Application of Prognostic Scoring in Systemic Mastocytosis Patients within a UK Centre of Excellence: Guys and St Thomas' NHS Foundation Trust.'. Blood, 2021, 138, 3625-3625.	0.6	0